XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX ...

OBJECTIVES To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout. METHODS Prospective, parallel, open study of 86 ...

The new drug development program - XRx-026 - will focus on the treatment of individuals who have gout and are intolerant to allopurinol. With the clinical development of XORLO TM 1 having advanced ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing We apologize, but this video has failed to load. Try refreshing ...

(MENAFN- GlobeNewsWire - Nasdaq) XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing With the clinical ...

Dr Hilary Jones, resident GP at ITV's Good Morning Britain, said he had discoloured nails, joint pain that would worsen at ...

Diagnosis Tophaceous gout associated with urate nephropathy in a patient intolerant to allopurinol. Management Acute polyarthritis was successfully managed by intravenous bolus methylprednisolone ...

cdhb.health.nz Objectives To determine the efficacy and safety of allopurinol dose escalation using a treat-to-target serum urate (SU) approach. Methods A randomised, controlled, parallel-group, ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filing CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX ...

Febuxostat is generally well tolerated but is significantly more expensive than allopurinol. Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to ...